DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 9.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $370,515 | -30.1% | 17,960 | +0.1% | 0.00% | -25.0% |
| Q2 2023 | $529,705 | +129412.2% | 17,950 | +1.1% | 0.00% | +33.3% |
| Q1 2023 | $409 | -17.9% | 17,758 | -0.9% | 0.00% | -25.0% |
| Q4 2022 | $498 | -99.9% | 17,918 | 0.0% | 0.00% | -20.0% |
| Q3 2022 | $544,000 | +3.8% | 17,918 | +0.6% | 0.01% | 0.0% |
| Q2 2022 | $524,000 | +523.8% | 17,816 | +581.0% | 0.01% | +400.0% |
| Q1 2022 | $84,000 | -36.4% | 2,616 | -32.1% | 0.00% | 0.0% |
| Q4 2021 | $132,000 | -57.4% | 3,851 | -37.3% | 0.00% | -50.0% |
| Q3 2021 | $310,000 | -36.2% | 6,146 | -0.8% | 0.00% | -33.3% |
| Q2 2021 | $486,000 | +35.4% | 6,194 | -1.6% | 0.00% | +50.0% |
| Q1 2021 | $359,000 | -26.6% | 6,294 | +7.7% | 0.00% | -33.3% |
| Q4 2020 | $489,000 | +425.8% | 5,844 | +125.6% | 0.00% | +200.0% |
| Q3 2020 | $93,000 | +416.7% | 2,590 | +240.8% | 0.00% | – |
| Q2 2020 | $18,000 | +125.0% | 760 | +65.2% | 0.00% | – |
| Q1 2020 | $8,000 | – | 460 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
| Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
| Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
| Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
| MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
| Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
| PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
| HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |